The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
19 Aug 2024
19 Aug 2024
Historique:
received:
02
03
2024
accepted:
13
06
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
aheadofprint
Résumé
The Eczema Area and Severity Index is an investigator-assessed instrument reporting clinical signs of atopic dermatitis. The instrument is extensively validated in both adult and paediatric populations and recommended as a core outcome measure to assess clinical signs by the Harmonising Outcome Measures for Eczema initiative in clinical trials and was recently recommended as an option to measure signs in clinical practice. Here, we review the validation of the instrument using standard assessment criteria, explore controversies and challenges to its universal applicability and highlight future electronic adaptations. We find that the instrument demonstrates adequate performance in the measurement properties recommended by the COnsensus-based Standards for the selection of health Measurement INstruments initiative for instruments reporting clinical signs, is clinically interpretable, and is suitable for all atopic dermatitis severities. Some validation gaps remain. Information reporting on its performance in diverse populations, with emphasis on deeply pigmented skin, is promising though limited. Technological adaptations are demonstrating promising initial validation results and may facilitate remote and/or automated assessments assisting clinical care and decentralized clinical trials in the future. We find no strong evidence limiting its use in trials or clinical practice although questions pertaining to the effect of investigator training remain. We recommend that the Eczema Area and Severity Index be used in all interventional atopic dermatitis trials and be considered alongside other recommended clinical practice severity instruments.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Tofte S, Graeber R, Cherill R, Omoto M, Thurston M, Hanifin J. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;S2(11):S197. https://doi.org/10.1016/S0926‐9959(98)95291‐6
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol. 2001;10(1):11–18. https://doi.org/10.1034/j.1600‐0625.2001.100102.x
Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The eczema area and severity index—a practical guide. Dermatitis. 2022;33(3):187–192. https://doi.org/10.1097/DER.0000000000000895
Schmitt J, Langan S, Williams HC, European Dermato‐Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120(6):1389–1398. https://doi.org/10.1016/j.jaci.2007.08.011
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337–1347. https://doi.org/10.1016/j.jaci.2013.07.008
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–807. https://doi.org/10.1016/j.jaci.2014.07.043
Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318–1325. https://doi.org/10.1111/bjd.13237
Vincent R, Chalmers JR, McWilliams C, Thomas KS, Dodd S, Rogers N, et al. Assessing uptake of the Harmonising outcome measures for eczema (HOME) Core outcome set and recommended instruments. Br J Dermatol. 2020;183(3):566–568. https://doi.org/10.1111/bjd.19030
Agnihotri G, Lio PA, Lee KC. Differences in pediatric versus adult clinical trial characteristics for atopic dermatitis. Pediatr Dermatol. 2021;38(4):775–779. https://doi.org/10.1111/pde.14658
Lam M, Spuls PI, Leshem YA, Gerbens LAA, Thomas KS, Arents B, et al. Reporting of Harmonising outcome measures for eczema (HOME) core outcome set instruments in randomized clinical trials for systemic treatments in atopic dermatitis. Br J Dermatol. 2023;189(4):494–496. https://doi.org/10.1093/bjd/ljad237
Grinich EE, Schmitt J, Küster D, Spuls PI, Williams HC, Chalmers JR, et al. Standardized reporting of the eczema area and severity index (EASI) and the patient‐oriented eczema measure (POEM): a recommendation by the Harmonising outcome measures for eczema (HOME) initiative. Br J Dermatol. 2018;179(2):540–541. https://doi.org/10.1111/bjd.16732
Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, et al. Measuring signs of atopic dermatitis in clinical practice: a HOME‐CP consensus statement. JAMA Dermatol. 2024. https://doi.org/10.1001/jamadermatol.2024.1162
Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient‐reported outcome measures. Qual Life Res. 2018;27(5):1147–1157. https://doi.org/10.1007/s11136‐018‐1798‐3
Mokkink MB, van der Vleuten CPM, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN risk of bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Med Res Methodol. 2020;20:293.
Charman CR, Venn AJ, Williams H. Measuring atopic eczema severity visually: which variables are most important to patients? [published correction appears in arch Dermatol. 2006 Jan;142(1):22. Bigby, Michael [removed]]. Arch Dermatol. 2005;141(9):1146–1151. https://doi.org/10.1001/archderm.141.9.1146
Shim WH, Park HJ, Kim HS, Kim SH, Ko HC, Kim MB, et al. Does the EASI score reflect itch severity? Ann Allergy Asthma Immunol. 2011;106(6):540–541. https://doi.org/10.1016/j.anai.2011.02.005
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357. https://doi.org/10.1111/bjd.13662
Zhao CY, Tran AQ, Lazo‐Dizon JP, Kim J, Daniel BS, Venugopal SS, et al. A pilot comparison study of four clinician‐rated atopic dermatitis severity scales. Br J Dermatol. 2015;173(2):488–497. https://doi.org/10.1111/bjd.13846
Yang HJ, Jeon YH, Pyun BY. Evaluation of patient's subjective severity using various scoring system in Korean children with atopic dermatitis. Asian Pac J Allergy Immunol. 2010;28(2–3):130–135.
Rullo VE, Segato A, Kirsh A, Sole D. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol. 2008;36(4):205–211.
Bożek A, Reich A. Assessment of intra‐ and inter‐rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology. 2017;233(1):16–22. https://doi.org/10.1159/000472711
Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–1321. https://doi.org/10.1111/bjd.15641
Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708–1710.e1. https://doi.org/10.1016/j.jaci.2017.04.052
Drucker AM, Matthews NH, Muglia J, Qureshi AA. Pilot study of the CAPS (clinical extent, area, pruritus, sleep) measure for atopic dermatitis severity. Ann Allergy Asthma Immunol. 2018;121(3):380–381.e4. https://doi.org/10.1016/j.anai.2018.05.027
Topham C, Haynes D, Brazil M, Simpson E. Initial validation of the product of the signs global assessment and body surface area in atopic dermatitis. J Am Acad Dermatol. 2021;84(2):283–289. https://doi.org/10.1016/j.jaad.2020.05.095
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. Measurement properties of the Rajka‐Langeland severity score in children and adults with atopic dermatitis. Br J Dermatol. 2021;184(1):87–95. https://doi.org/10.1111/bjd.19159
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2021;35(1):180–187. https://doi.org/10.1111/jdv.16846
Suh TP, Ramachandran D, Patel V, Jackson KL, Rangel SM, Fishbein AB, et al. Product of investigator global assessment and body surface area (IGAxBSA): a practice‐friendly alternative to the eczema area and severity index to assess atopic dermatitis severity in children. J Am Acad Dermatol. 2020;82(5):1187–1194.
Simpson EL, Bissonnette R, Paller AS, King B, Silverberg JI, Reich K, et al. The validated investigator global assessment for atopic dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis. Br J Dermatol. 2022;187(4):531–538. https://doi.org/10.1111/bjd.21615
Paller AS, Tan JKL, Bagel J, Rossi AB, Shumel B, Zhang H, et al. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. Br J Dermatol. 2022;186(3):496–507. https://doi.org/10.1111/bjd.20872
Baek JH, Park CW, Choi KM, Yang YS, Lee SY, Koh JS, et al. The atopic dermatitis antecubital severity score: validity, reliability, and sensitivity to change in patients with atopic dermatitis. Int J Dermatol. 2015;54(12):1382–1389. https://doi.org/10.1111/ijd.12711
Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96–102. https://doi.org/10.1111/j.1365‐2133.2004.05696.x
Hurault G, Schram ME, Roekevisch E, Spuls PI, Tanaka RJ. Relationship and probabilistic stratification of eczema area and severity index and objective scoring atopic dermatitis severity scores for atopic dermatitis. Br J Dermatol. 2018;179(4):1003–1005. https://doi.org/10.1111/bjd.16916
Breuer K, Braeutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004;209(4):314–320. https://doi.org/10.1159/000080855
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. https://doi.org/10.1111/j.1398‐9995.2011.02719.x
Ridd MJ, Gaunt DM, Guy RH, Redmond NM, Garfield K, Hollinghurst S, et al. Comparison of patient (POEM), observer (EASI, SASSAD, TIS) and corneometry measures of emollient effectiveness in children with eczema: findings from the COMET feasibility trial. Br J Dermatol. 2018;179(2):362–370. https://doi.org/10.1111/bjd.16475
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health‐related patient‐reported outcomes. J Clin Epidemiol. 2010;63(7):737–745. https://doi.org/10.1016/j.jclinepi.2010.02.006
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study. Br J Dermatol. 2021;184(5):888–895. https://doi.org/10.1111/bjd.19457
Simpson E, Bissonnette R, Eichenfield LF, Guttman‐Yassky E, King B, Silverberg JI, et al. The validated investigator global assessment for atopic dermatitis (vIGA‐AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846. https://doi.org/10.1016/j.jaad.2020.04.104
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31. https://doi.org/10.1159/000247298
Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294. https://doi.org/10.1016/j.jaad.2015.09.062
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double‐blind studies. J Am Acad Dermatol. 2021;85(4):863–872. https://doi.org/10.1016/j.jaad.2021.04.085
Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, et al. Translating the Investigator's static global assessment to the eczema area and severity index in studies of Crisaborole for atopic dermatitis. Dermatol Ther. 2021;11(3):845–853. https://doi.org/10.1007/s13555‐021‐00509‐9
Brunner PM, Guttman‐Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449–455. https://doi.org/10.1016/j.anai.2018.11.015
Ben‐Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147(5):920–925. https://doi.org/10.1046/j.1365‐2133.2002.04965.x
Zhao CY, Wijayanti A, Doria MC, Harris AG, Jain SV, Legaspi KN, et al. The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: a grey area. Int J Womens Dermatol. 2015;1(3):150–154.
Zhao CY, Hao EY, Oh DD, Daniel BS, Martin LK, Su JC, et al. A comparison study of clinician‐rated atopic dermatitis outcome measures for intermediate‐ to dark‐skinned patients. Br J Dermatol. 2017;176(4):985–992.
Silverberg JI, Horeczko J, Alexis A. Development of an Eczema area and severity index atlas for diverse skin types. Dermatitis. 2024;35(2):173–177. https://doi.org/10.1089/derm.2023.0051
Tremp M, Knafla I, Burg G, Wüthrich B, Schmid‐Grendelmeier P. ‘EASIdig’—a digital tool to document disease activity in atopic dermatitis. Dermatology. 2011;223(1):68–73. https://doi.org/10.1159/000330333
Hughes ME, Aralis H, Bruhn KW, Cotliar J, Craft N, DeLuca IJ, et al. A reliability study using network‐oriented research assistant to evaluate the use of digital photographs in the assessment of atopic dermatitis. J Am Acad Dermatol. 2021;85(3):725–726. https://doi.org/10.1016/j.jaad.2019.01.043
Ali Z, Chiriac A, Bjerre‐Christensen T, Isberg AP, Dahiya P, Manole I, et al. Mild to moderate atopic dermatitis severity can be reliably assessed using smartphone‐photographs taken by the patient at home: a validation study. Skin Res Technol. 2022;28(2):336–341. https://doi.org/10.1111/srt.13136
Croce EA, Rathouz PJ, Lopes FCPS, Leszczynska M, Diaz LZ, Levy ML, et al. Validation of remote atopic dermatitis severity assessment with the eczema area and severity index in children using caregiver‐provided photos and videos. Pediatr Dermatol. 2024;39(4):547–552. https://doi.org/10.1111/pde.15003
Bang CH, Yoon JW, Ryu JY, Chun JH, Han JH, Lee YB, et al. Automated severity scoring of atopic dermatitis patients by a deep neural network [published correction appears in Sci Rep. 2021 Jul 27;11(1):15640]. Sci Rep. 2021;11(1):6049. https://doi.org/10.1038/s41598‐021‐85489‐8
Schaap MJ, Cardozo NJ, Patel A, de Jong EMGJ, van Ginneken B, Seyger MMB. Image‐based automated psoriasis area severity index scoring by convolutional neural networks. J Eur Acad Dermatol Venereol. 2022;36(1):68–75. https://doi.org/10.1111/jdv.17711
Blauvelt A, Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019;181(1):196–197. https://doi.org/10.1111/bjd.17703
Simpson EL, de Bruin‐Weller M, Hong HC, Staumont‐Sallé D, Blauvelt A, Eyerich K, et al. Lebrikizumab provides rapid clinical responses across all eczema area and severity index body regions and clinical signs in adolescents and adults with moderate‐to‐severe atopic dermatitis. Dermatol Ther. 2024;14(5):1145–1160. https://doi.org/10.1007/s13555‐024‐01158‐4